Allena Pharmaceuticals, Inc. EBITDA

EBITDA of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA growth rates and interactive chart. Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company's operating performance. Essentially, it's a way to evaluate a company's performance without having to factor in depreciation, interest expenses (debt), writedowns or other accounting measures and taxes. EBITDA, however, can be misleading because it strips out the cost of capital investments like property, plant, and equipment. To calculate EBITDA, take operating profit (also called EBIT) and add back depreciation and amortization.

Highlights and Quick Summary

  • EBITDA for the quarter ending March 31, 2022 was $-11.4 Million (a 15.38% increase compared to previous quarter)
  • Year-over-year quarterly EBITDA decreased by -15.32%
  • Annual EBITDA for 2021 was $-46.9 Million (a 50.27% increase from previous year)
  • Annual EBITDA for 2020 was $-31.2 Million (a -33.23% decrease from previous year)
  • Annual EBITDA for 2019 was $-46.8 Million (a 31.65% increase from previous year)
  • Twelve month EBITDA ending March 31, 2022 was $-47.1 Million (a 0.36% increase compared to previous quarter)
  • Twelve month trailing EBITDA increased by 11.09% year-over-year
Trailing EBITDA for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-47.1 Million $-46.9 Million $-46.7 Million $-42.4 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA of Allena Pharmaceuticals, Inc.

Most recent EBITDAof ALNA including historical data for past 10 years.

Interactive Chart of EBITDA of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. EBITDA for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-11.43
2021 $-9.91 $-12.24 $-13.5 $-11.26 $-46.91
2020 $-9.74 $-7.88 $-6.52 $-7.48 $-31.22
2019 $-11.25 $-13.3 $-11.3 $-11.52 $-46.76
2018 $-9.75 $-9.69 $-8.13 $-7.95 $-35.52
2017 $-6.55 $-4.34 $-4.45 $-5.5 $-20.88
2016 $-6.1 $-23.99
2015 $-13.81

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.